mRNA-4157/V940 Research for Non-Small Cell Lung Cancer (Adjuvant)
An evidence-based overview of research examining mRNA-4157/V940 in the context of non-small cell lung cancer (adjuvant). This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 3 INTerpath-002 trial is evaluating mRNA-4157 plus pembrolizumab vs pembrolizumab alone in resected stage II-IIIB NSCLC. Approximately 860 patients targeted. High mutation burden in NSCLC creates favorable conditions for neoantigen targeting.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. mRNA-4157/V940 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.